Alzheimer’s Association has asked the Centers for Medicare & Medicaid Services (CMS) to provide full and unrestricted coverage of FDA-approved Alzheimer’s treatments. This comes after lecanemab, a drug that removes amyloid from brain, was rejected as a treatment for Alzheimer’s. The Alzheimer’s Association said there are more than 300 Alzheimer’s treatments in clinical trials.